4-aminopyridine has been researched along with Parkinson Disease in 6 studies
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Bancroft, EA | 1 |
| De La Mora, M | 1 |
| Pandey, G | 1 |
| Zarate, SM | 1 |
| Srinivasan, R | 1 |
| Shi, L | 1 |
| Jia, L | 1 |
| Wang, Y | 1 |
| Xiu, M | 1 |
| Xie, J | 1 |
| Li, S | 1 |
| Wei, D | 1 |
| Mao, Z | 1 |
| Chen, L | 1 |
| Yan, X | 1 |
| Li, Y | 1 |
| Dong, S | 1 |
| Wang, D | 1 |
| Luca, CC | 3 |
| Nadayil, G | 1 |
| Dong, C | 1 |
| Nahab, FB | 1 |
| Field-Fote, E | 1 |
| Singer, C | 3 |
1 review available for 4-aminopyridine and Parkinson Disease
| Article | Year |
|---|---|
Can 4-aminopyridine modulate dysfunctional gait networks in Parkinson's disease?
Topics: 4-Aminopyridine; Animals; Gait; Humans; Nerve Net; Neurons; Parkinson Disease; Potassium Channel Blo | 2013 |
1 trial available for 4-aminopyridine and Parkinson Disease
| Article | Year |
|---|---|
Dalfampridine in Parkinson's disease related gait dysfunction: A randomized double blind trial.
Topics: 4-Aminopyridine; Aged; Cross-Over Studies; Double-Blind Method; Female; Follow-Up Studies; Gait; Hum | 2017 |
4 other studies available for 4-aminopyridine and Parkinson Disease
| Article | Year |
|---|---|
Extracellular S100B inhibits A-type voltage-gated potassium currents and increases L-type voltage-gated calcium channel activity in dopaminergic neurons.
Topics: 4-Aminopyridine; Animals; Calcium; Calcium Channels, L-Type; Dopaminergic Neurons; Male; Mice; Parki | 2022 |
4-Aminopyridine Protects Nigral Dopaminergic Neurons in the MPTP Mouse Model of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 4-Aminopyridine; Animals; Disease Models, Animal; Dopa | 2023 |
Design, synthesis, immunocytochemistry evaluation, and molecular docking investigation of several 4-aminopyridine derivatives as potential neuroprotective agents for treating Parkinson's disease.
Topics: 4-Aminopyridine; alpha-Synuclein; Animals; Cell Proliferation; Cell Survival; Cells, Cultured; Dose- | 2017 |
4-aminopyridine improves freezing of gait in Parkinson's disease.
Topics: 4-Aminopyridine; Follow-Up Studies; Gait Disorders, Neurologic; Humans; Male; Parkinson Disease; Pot | 2013 |